Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott's Top India Product Phensedyl Nosedives As India Faces Severe Codeine Shortage

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Drug maker Abbott may have leaped to the lead position in the Indian market with the much-hyped acquisition of Piramal Healthcare's formulations business, but data shows a three-fold sales decline of its lead brand, the cough syrup Phensedyl (chlorpheniramine/codeine), in the last eight months

You may also be interested in...



Abbott India Confident Despite Phensedyl Problems

Abbott India, part of the US-based global healthcare company, says it is confident about the safety of its popular cough syrup Phensedyl, after it was reported that a government laboratory test found a sample bottle allegedly contained an excessive amount of codeine.

Abbott India Confident Despite Phensedyl Problems

Abbott India, part of the US-based global healthcare company, says it is confident about the safety of its popular cough syrup Phensedyl, after it was reported that a government laboratory test found a sample bottle allegedly contained an excessive amount of codeine.

India's Sales Rankings Shuffle As IMS Health Widens Audit To Hospitals And Doctors

MUMBAI - GlaxoSmithKline PLC gained the top sales slot in India with Augmentin (amoxicillin/clavulanate) as a result of data analysis firm IMS Health expanding its sales audit coverage in the country

Related Content

UsernamePublicRestriction

Register

SC143162

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel